Biotech Values

[biomaven0]

>DVAX

This report claims it's roughly a $1B market:

http://finance.yahoo.com/news/hepatitis-b-vaccines-pipeline-assessment-104100550.html

Don't know how much of that is under 18.

The significance of the move for me lies as much in what it says about the FDA's attitude to the NDA as it does about the market. (Folks will recall that the reason for the original restriction were safety concerns from an earlier trial that now seem to have been resolved).

Very likely munch candidate in my view.

Peter